Sometimes the stock market gets excited about blockbuster cancer drugs or revolutionary AI chips. And sometimes it gets excited about something that will help you not throw up on a boat. Vanda Pharmaceuticals (VNDA) had one of those latter moments Tuesday, with shares surging 20.20% to $8.45 in after-hours trading after announcing FDA approval for NEREUS, its new motion sickness treatment.
This matters because NEREUS (tradipitant) represents the first new approach to motion sickness in over four decades. It's an oral neurokinin-1 receptor antagonist, which is fancy talk for a drug that blocks certain brain signals involved in nausea and vomiting. And unlike your grandfather's Dramamine, this one is grounded in what Vanda calls "modern neuropharmacology."
The Clinical Evidence Is Impressive
Vanda didn't just squeak by with marginal results. In the Motion Syros trial, which included 365 patients, only 18.3% to 19.5% of people taking NEREUS experienced vomiting, compared with 44.3% in the placebo group. That's statistically significant at p < 0.0001, meaning the results weren't just lucky noise.
The Motion Serifos study with 316 patients showed even better outcomes. Vomiting rates ranged from just 10.4% to 18.3% with NEREUS, versus 37.7% with placebo (p ≤ 0.0014). We're talking about risk reductions of more than 50% to 70%, which is the kind of efficacy that gets FDA stamps of approval.
The side effect profile looks manageable too. Common adverse reactions included somnolence in 6% to 12% of patients and fatigue in 6% to 8%. So yes, the drug might make you sleepy, but that's arguably better than spending your cruise hanging over the railing.
A Massive Market Opportunity
Here's where the commercial potential gets interesting. According to the Washington-based biotech, approximately 25% to 30% of U.S. adults experience motion sickness during routine travel. That translates to roughly 65 million to 78 million people. Even more compelling, about 5% to 15% of those folks experience severe, recurrent symptoms, representing a core market desperately seeking better options.
Mihael H. Polymeropoulos, president, CEO and chairman of Vanda Pharmaceuticals, framed the approval in historical terms: "For the first time in over 40 years, patients have access to a novel therapy grounded in modern neuropharmacology."
Pipeline Extensions and Launch Timeline
Vanda isn't stopping with motion sickness. The company is also advancing tradipitant in clinical development for gastroparesis, a chronic digestive disorder, and for preventing nausea and vomiting caused by GLP-1 receptor agonists. That last indication is particularly timely given the explosion in drugs like Ozempic and Wegovy, which often come with gastrointestinal side effects.
NEREUS was licensed from Eli Lilly and Company (LLY), and Vanda expects to launch the drug commercially in the coming months.
What the Charts Say
From a technical perspective, VNDA is showing momentum. The stock closed Tuesday's regular session at $7.03, down 2.36%, before the after-hours pop. With a market capitalization of $415.45 million, the stock has a 52-week range of $3.81 to $7.47.
Over the past 12 months, VNDA has gained 47.07%, reflecting a strong long-term uptrend. The relative strength index sits at 65.44, and the stock is trading at 88% of its 52-week range, suggesting bullish sentiment but also approaching overbought territory. Translation: there's momentum here, but don't chase blindly.
The stock's strong momentum lands it in the 90th percentile, indicating a positive price trend across multiple timeframes. For investors who missed the after-hours jump, the question becomes whether there's more room to run or if this is a case of buy the rumor, sell the news playing out in reverse.
